FDA Approves AstraZeneca’s IMFINZI® (durvalumab) Plus Chemotherapy to Treat Severe Types of Endometrial Cancer
AstraZeneca’s new therapy approval was based on the DUO-E trial results, which proved that IMFINZI can reduce disease progression or death by 58% compared to chemotherapy.
read more..